Newsroom | 69023 results

LOS ANGELES--(BUSINESS WIRE)--AltaSea at the Port of Los Angeles, the world’s leading tech hub for the blue economy, today announced the appointment of businessman and philanthropist Jon Sutton Day to its Board of Trustees, effective March 31. A lifelong Angeleno, Day currently serves on the Board of Directors of the W.M. Keck Foundation, one of the nation’s largest philanthropic foundations supporting medical research, science and engineering, and educational programs. He is on the Foundation’...

STILLWATER, Minn. & TEL AVIV, Israele--(BUSINESS WIRE)--Sub‑Q Bionics, azienda produttrice di dispositivi medici che sviluppa un innovativo sistema di drenaggio impiantabile progettato per aiutare i pazienti affetti da linfedema a gestire meglio i loro sintomi, oggi ha annunciato un accordo di licenza con la Mayo Clinic. L'accordo prevede la concessione della licenza di know-how clinico in tema di chirurgia ricostruttiva e linfatica da parte della Mayo Clinic a Sub-Q Bionics. Nell'ambito di que...

STILLWATER, Minn. & TEL AVIV, Israël--(BUSINESS WIRE)--Sub-Q Bionics, een bedrijf in medische hulpmiddelen dat een innovatief implanteerbaar lymfedrainagesysteem ontwikkelt om patiënten met lymfoedeem te helpen hun symptomen beter te beheersen, heeft vandaag een licentieovereenkomst met de Mayo Clinic aangekondigd. Via deze overeenkomst heeft Sub-Q Bionics klinische knowhow van de Mayo Clinic verkregen met betrekking tot reconstructieve en lymfatische chirurgie. Als onderdeel van deze samenwerk...

STILLWATER, Minn. & TEL AVIV, Israel--(BUSINESS WIRE)--Sub‑Q Bionics, una empresa de dispositivos médicos que desarrolla un innovador sistema implantable de drenaje linfático diseñado para ayudar a los pacientes con linfedema a controlar mejor sus síntomas, ha anunciado hoy la firma de un acuerdo de licencia con la Mayo Clinic. En virtud de este acuerdo, Sub-Q Bionics ha obtenido una licencia de la Mayo Clinic para utilizar sus conocimientos clínicos en materia de cirugía reconstructiva y linfá...

STILLWATER, Minn. & TEL AVIV, Israël--(BUSINESS WIRE)--Sub-Q Bionics, la société de dispositifs médicaux développant un système innovant de drainage lymphatique implantable conçu pour aider les patients atteints de lymphœdème à mieux gérer leurs symptômes, a annoncé aujourd'hui la conclusion d'un accord de licence avec la Mayo Clinic. Dans le cadre de cet accord, Sub-Q Bionics a obtenu une licence sur le savoir-faire clinique de la Mayo Clinic en matière de chirurgie reconstructive et lymphatiq...

STILLWATER, Minn. & TEL AVIV, Israel--(BUSINESS WIRE)--Sub-Q Bionics, ein Medizintechnikunternehmen, das ein innovatives implantierbares lymphatisches Drainagesystem entwickelt, das Menschen mit Lymphödem dabei unterstützen soll, ihre Symptome besser zu bewältigen, gab heute eine Lizenzvereinbarung mit der Mayo Clinic bekannt. Im Rahmen der Vereinbarung hat Sub-Q Bionics klinisches Fachwissen der Mayo Clinic zur rekonstruktiven Chirurgie und zur Chirurgie des Lymphsystems in Lizenz übernommen....

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics launches Dyno Psi-Phi, an agentic AI suite for protein binder design, at NVIDIA GTC 2026...

SALT LAKE CITY--(BUSINESS WIRE)--The addition of APEXecm reflects Kolosis's continued commitment to developing and commercializing best-in-class solutions for the surgical community....

RALEIGH, N.C.--(BUSINESS WIRE)--On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan. The transaction was led by HarbourVest Partners, LLC (“HarbourVest”), with Pantheon Ventures, L.P. participating as a significan...

NEW YORK--(BUSINESS WIRE)--Sunrise Group, a pioneer in medical device innovation and sleep care, today announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading international medical journal. Supported by the French Ministry of Health through the Forfait Innovation program, this study is the largest randomized controlled trial to date evaluating an at-home diagnostic pathway for obstructive sleep apnea (OSA) compared with gold-standard pol...